Clinical Trial Detail

NCT ID NCT03950570
Title ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Orinove, Inc.
Indications

Her2-receptor negative breast cancer

breast cancer

triple-receptor negative breast cancer

Advanced Solid Tumor

Therapies

ORIN1001 + Paclitaxel

ORIN1001

Age Groups: adult senior

No variant requirements are available.